Literature DB >> 3958138

Emergence of bactericidal and opsonizing antibody to Vibrio vulnificus following bacterial infection.

D M Musher, M V Hansen, A Goree, F Gyorkey, A J Chapman, R E Baughn.   

Abstract

Virulent isolates of Vibrio vulnificus resist the bactericidal and opsonizing effects of normal human serum, in contrast to environmental isolates, which are highly serum susceptible. Immune responses to bacteremic V. vulnificus infections in human subjects have not been characterized. Serum from a patient who survived sepsis caused by V. vulnificus had substantial bactericidal and opsonizing immunoglobulin G (IgG) for his own bloodstream isolate. Killing was mediated by the classical complement pathway, whereas opsonization was effected by either the classical or the alternative pathway. IgG that reacted strongly with 55-, 58-, and 68-kilodalton outer membrane proteins was present in the patient's convalescent-phase serum but was absent from normal human serum. These findings suggest that humoral immunity to V. vulnificus, mediated by bactericidal and opsonizing antibody, emerges during infection and may be due, in part, to IgG directed against identifiable outer membrane proteins.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958138      PMCID: PMC268664          DOI: 10.1128/jcm.23.3.411-415.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  29 in total

1.  Western blot analysis of the human antibody response to Campylobacter jejuni cellular antigens during gastrointestinal infection.

Authors:  I Nachamkin; A M Hart
Journal:  J Clin Microbiol       Date:  1985-01       Impact factor: 5.948

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Nontypable Haemophilus influenzae are unencapsulated both in vivo and in vitro.

Authors:  F Gyorkey; D Musher; P Gyorkey; A Goree; R Baughn
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

4.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

5.  Protection of mice against Vibrio vulnificus disease by vaccination with surface antigen preparations and anti-surface antigen antisera.

Authors:  A S Kreger; L D Gray; J Testa
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

6.  Differential complement activation and susceptibility to human serum bactericidal action by Vibrio species.

Authors:  M L Tamplin; S Specter; G E Rodrick; H Friedman
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

7.  Resistance of Vibrio vulnificus to serum bactericidal and opsonizing factors: relation to virulence in suckling mice and humans.

Authors:  D E Johnson; F M Calia; D M Musher; A Goree
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

8.  Immunogenic proteins in cell-free culture supernatants of Haemophilus influenzae type b.

Authors:  P A Gulig; G H McCracken; P L Holmans; E J Hansen
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

9.  High-molecular-weight antigenic protein complex in the outer membrane of Neisseria gonorrhoeae.

Authors:  W J Newhall; C E Wilde; W D Sawyer; R A Haak
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

10.  Analysis of the antigen specificity of the human serum immunoglobulin G immune response to complicated gonococcal infection.

Authors:  E W Hook; D A Olsen; T M Buchanan
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

View more
  2 in total

Review 1.  Vibrio vulnificus: disease and pathogenesis.

Authors:  Melissa K Jones; James D Oliver
Journal:  Infect Immun       Date:  2009-03-02       Impact factor: 3.441

Review 2.  Current perspectives on the epidemiology and pathogenesis of clinically significant Vibrio spp.

Authors:  J M Janda; C Powers; R G Bryant; S L Abbott
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.